Start patients on NUPLAZID® (pimavanserin) 34 mg—the only FDA-approved therapy proven to reduce delusions and hallucinations associated with PD psychosis in elderly patients.1,2
ONE FDA-approved treatment, ONE small* capsule, ONE daily dose
Reduces PD-related delusions and hallucinations without impacting motor function
Demonstrated safety profile in elderly patients† with PD psychosis
In vitro, a serotonergic agent with no appreciable affinity for D2, histamine, muscarinic, or adrenergic receptors‡
*Actual size is 14.3 mm X 5.3 mm.
†The maximum age in the clinical studies was 90 years old.3
‡The precise mechanism of action of NUPLAZID is unclear but is thought to be mediated through a combination of inverse agonist and antagonist activity. However, the effect of NUPLAZID could be mediated through a combination of inverse agonist and antagonist activity at serotonin 5-HT2A receptors and to a lesser extent at serotonin 5-HT2C receptors.1
NUPLAZID is proven to reduce delusions and hallucinations associated with PD psychosis in elderly patients1,2
NUPLAZID showed continuous improvement over 6 weeks
Results from a Phase 3, randomized, multicenter, double-blind, placebo-controlled, parallel-group study of PD psychosis patients (N=199).1,2 Primary endpoint was change from baseline at 6 weeks in the 9-item SAPS-PD. Doses of PD medications taken prior to baseline were required to be stable 30 days prior to study start and throughout the study period. Mean baseline score was 15.9 for NUPLAZID and 14.7 for placebo. The mean age of patients enrolled in the clinical study with NUPLAZID was 72 years.2 While the primary endpoint was designed to measure change from baseline to Week 6, a statistically significant difference between NUPLAZID and placebo was observed at Week 4 (P=0.0369) and again at Week 6 (P=0.0014).
LSM=least-squares mean; SAPS-PD=Scale for Assessment of Positive Symptoms-Parkinson’s Disease; SE=standard error.
Treat PD-related delusions and hallucinations without impacting motor function1,2
NUPLAZID 34 mg did not impact motor function or motoric activities of daily living compared to placebo.*
*As measured by United Parkinson’s Disease Rating Scale Parts II and III (UPDRS II+III).
NUPLAZID has a demonstrated safety profile proven in elderly patients with PD psychosis1
In the 6-week studies, the maximum age was 90 years.3